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Diabetic retinopathy (DR) is the most serious ocular
complication of type 1 diabetes (T1D) and leading cause
of acquired blindness in working aged adults. Although
various interventions have been trialled to prevent the
development or progression of DR, the evidence to sup-
port many of these remains unclear. We systematically
reviewed the evidence for primary and secondary inter-
ventions, to guide the management of DR in people
with T1D.
Systematic searches were performed using MEDLINE,
EMBASE and CENTRAL databases (from January 1990
to June 2014) to identify randomised controlled trials
and controlled cohort studies reporting the incidence or
progression of DR following administration of systemic
interventions. English-language studies with a minimum
follow-up of one year were eligible. Meta-analyses of
extracted data were performed to determine pooled rela-
tive risk (RR) reduction.
Twenty-three studies met the inclusion criteria. Inten-
sive insulin therapy significantly reduced the risk of both
incident DR (RR 0.44, 95% CI 0.22-0.86, p=0.02) and pro-
gression of DR (RR 0.55, 0.31-0.97, p=0.04) compared
with conventional therapy. Continuous subcutaneous
insulin infusion (CSII) pumps provided significantly
greater protection than multiple daily injection therapy
(RR 0.33, 95% CI 0.19-0.57, p<0.0001). Angiotensin-
converting enzyme inhibition had no impact on DR
incidence but reduced progression (RR 0.57, 95% CI
0.34-0.94, p=0.03). Conversely, angiotensin receptor
blockade was effective in decreasing DR incidence (RR
0.65, 95% CI 0.49-0.85, p=0.002) but had non-significant
effect on progression. Both pancreas-alone and combined
pancreas-kidney transplantation retarded progression of
DR (RR 0.20, 95% CI 0.10-0.41, p<0.0001). Islet cell
transplantation provided no benefit compared with either
intensive or conventional insulin therapy.
In people with T1D, there is strong evidence sup-
porting intensive insulin therapy for prevention of DR.
Anti-hypertensives also provide protection against DR
in normotensive, normoalbuminuric adults but their
effectiveness in other populations is yet to be investi-
gated. In patients with T1D of longer duration, pan-
creas transplantation slows progression of DR. There is
insufficient evidence to recommend the use of anti-
lipid therapy or other medical interventions.
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